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Summary
Since the early beginning of allergology as a science considerable efforts have been made by
clinicians and researchers to identify and characterize allergic triggers as raw allergenic
materials, allergenic sources and tissues, and more recently basic allergenic structures deﬁned
as molecules. The last 15–20 yearshave witnessed manycentres focusing on the identiﬁcation
and characterization of allergenic molecules leading to an expanding wealth of knowledge.
The need to organize this information leads to the most important question ‘when does a
protein become an allergen?’ In this article, I try to address this question by reviewing a few
basic concepts of the immunology of IgE-mediated diseases, reporting on the current
diagnostic and epidemiological tools used for allergic disease studies and discussing the
usefulness of novel biotechnology tools (i.e. proteomics and molecular biology approaches),
information technology tools (i.e. Internet-based resources) and microtechnology tools (i.e.
proteomic microarray for IgE testing on molecular allergens). A step-wise staging of the
identiﬁcation and characterization process, including bench, clinical and epidemiological
aspects, is proposed, in order to classify allergenic molecules dynamically. This proposal
reﬂects the application and use of all the new tools available from current technologies.
Introduction
More than a century of allergology has been dedicated to
the discovery of allergenic sources that cause IgE-
mediated diseases. This has involved a step-by-step pro-
cess moving from identiﬁcation of raw material causing
allergic reactions (i.e. house dust) to organisms and tissues
as triggers (i.e. pollen, fruits, mites, fungi). Raw materials,
organisms and their tissues have been used and are still in
use for diagnostic and therapeutic purposes as allergenic
extracts. Although considerable efforts have been made
by manufacturers and authorities to control allergenic
extract composition, the best deﬁnition for an allergenic
extract is still ‘an unpredictable mixture of allergenic and
non-allergenic compounds’. The application to allergen
discovery of new biochemical methods during the late
1970s and the 1980s has led to the identiﬁcation of the
real primary sensitizer and trigger, the allergenic mole-
cule. A further spike in allergenic molecule research has
been brought about by the progressive and rapid intro-
duction of molecular biology techniques into this research
ﬁeld. Neither the environmental allergenic source identi-
ﬁcation process nor the characterization of allergenic
molecules has reached a plateau phase, the former being
a consequence of both the increasing exposure to novel
organisms or the increasing awareness of allergy as the
cause of symptoms, and the latter being the consequence
of an increasing number of research centres working on
allergenic molecule identiﬁcation and characterization.
Both processes are further inﬂuenced by an increasing
world-wide interest in the ﬁeld of allergic diseases, mostly
in emerging countries. Such a historical trend is readily
depicted by monitoring and reporting the number of
newly identiﬁed allergenic molecules and the number of
papers published in the scientiﬁc literature from 323
papers in 2000 compared with 870 in 2007 (Fig. 1). This
has involved an increasing range of publications from
allergy and immunology to biochemical, agricultural and
environmental journals. This increase in the knowledge of
potentially allergenic molecules requires a systematic
organization and a clear deﬁnition of the criteria for
deﬁning what comprises an allergen, starting from the
very ﬁrst questions: ‘what are we going to classify?’ or
‘which is the structure to be deﬁned as allergenic?’ or
‘should we consider all the IgE-binding structures?’ To
address the need to bring sense and organization to the
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to brieﬂy consider some critical aspects of the IgE immune
response, report on the current diagnostic and epidemio-
logical tools used for allergic disease studies and the need
to implement them and lastly discuss the usefulness of
novel biotechnology, information technology and micro-
technology tools.
The immunoglobulin E immune response
IgE as a defence provided by the human system seems to
be evolutionarily linked to parasite infections [1], not least
because of the very high IgE levels generally detected in
parasite infection-affected subjects. It is interesting that
allergic reactions are rarely described in such patients
although they have speciﬁc IgE and antigen exposure at
the same time. Besides the relevance to infection with
helminthic parasites, IgE has been studied because of its
role in causing allergic diseases. Such an IgE response
differs markedly from the response to parasite antigens as
it does not protect from any infective agent and can
instead cause disease. Thus, we have the same antibody
recognizing different structures depending on the in-
volved organism and playing or not playing a pathogenic
role. This distinction is not exclusive to the dichotomy
between parasite and allergenic organisms, but also exists
within the IgE recognition of allergenic sources them-
selves. It is now accepted that IgE from allergic indivi-
duals can recognize antigenic non-parasite-related
structures from allergens and non-allergens without any
related symptoms [2]. A paradigmatic example is IgE
recognition of glycan side chains of glycoproteins [3].
Such IgE seems to be unable to trigger allergic symptoms
as shown by the negative double-blind placebo-controlled
oral challenge with recombinant human lactoferrin pro-
duced in rice as a model of plant multiple glycosylation
IgE-binding structure [4]. Overall, the condition of having
IgE with or without clinical symptoms can be reported for
almost any allergen [2].
At the end of this ﬁrst section, we can assume that IgE
can recognize allergenic and non-allergenic structures and
may or may not trigger allergic symptoms. Compared with
other human diseases, where two conditions are recorded
asthe absenceorthe presenceofasymptomaticdisease (i.e.
diabetes, hypertension), measured by the alteration of a
single parameter (i.e. blood glucose, blood pressure), if a
general population is examined we might record three
conditions by using speciﬁc IgE detection: (1) no speciﬁc
IgE; (2) speciﬁc IgE sensitization to a given allergen with-
out any clinical symptoms upon exposure; and (3) speciﬁc
IgE sensitization with different severity degrees of clinical
symptoms upon exposure to different levels of allergenic
molecules. These three conditions should be kept in mind
when deﬁning a molecule as an allergen along with the
assumptionthat theIgE-binding propertyisnotanintrinsic
feature of any protein but it is by deﬁnition the interaction
of two molecules: the antigen and the IgE.
The diagnostic and epidemiological approach
For routine diagnostic purposes or to deﬁne the magni-
tude of allergic sensitization within a given cohort exam-
ined for epidemiological purposes, we currently use the
skin prick test (which indirectly shows us the presence of
speciﬁc IgE) and direct IgE detection on serum samples by
several in vitromethods. In either case, we never make any
conclusion about the clinical relevance of the ﬁndings
based solely on in vivo and in vitro tests. We need to
carefully explore the patient’s history searching for evi-
dence of a reliable temporal relationship between allergen
exposure and symptom appearance or the individual
reactivity by challenging target organs. In the absence of
a positive clinical or challenge history, we conclude that
the subject is asymptomatic for that given IgE-binding
structure. The immunological dichotomy described above
is thus deﬁned by the clinical perspective, but it is only
from the same testing procedures that we can start the
process of classifying compounds as IgE-binding struc-
tures. Historically, it is from evidence that exposure causes
allergy symptoms that we start the process of identifying
Fig. 1. (a) Last 40 years’ time course of new allergen identiﬁcation
reported by either the cumulative number (line) or the newly identiﬁed
one (shaded area). (b) Last 40 years’ time course of published papers
reporting on any aspect related to allergenic molecules, as cumulative
number (left graph) and by years (right graph). The dashed vertical line
indicates Allergome web release (http://www.allergome.org).
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identiﬁed, several steps are required before the protein can
be fully documented as an allergen. Table 1 reports an
ideal process for a comprehensive deﬁnition of the char-
acteristics of an allergenic molecule. If we take as for
example some allergens that have been identiﬁed 20 years
ago or more, like Der p 1 or Bet v 1, we see from the
literature that they could reach the 14 evaluation stage
nowadays, having only occasional studies in the 15 or the
16 evaluation stages. In an almost 10-year range, Pru p 3
has reached 124 publications with just one epidemiologi-
cal study, leading the allergen to be scored 14. If we apply
the 12-step approach to the allergen identiﬁcation and
characterization process, allergens listed in any online
publicly accessible repository would range between the
1 and 12 stages. Two different approaches are currently
identiﬁable within the allergen characterization process:
immunochemical identiﬁcation lacking any biochemical
characterization and the direct cloning of the molecule.
The former is mostly applied when a polyclonal, IgG or IgE
isotype, from either humans or experimental animals, or a
monoclonal antibody are available for an already character-
ized homologous molecule. If the antibody is puriﬁed and
the allergen speciﬁcity is known, the presence of the allergen
can be deduced. Antibodies other than IgE give us just the
idea that the molecule is in the extract, rather than informa-
tion about its allergenic nature. IgE inhibition by a pre-
viously puriﬁed allergen is another immunochemical
method to detect and describe an IgE-binding structure
within a given allergenic extract. The direct cloning of the
allergen is the second strategy adopted when the amount of
molecule recoverable from the allergenic extract is too low
for any analytical and preparative use or to speed up
allergenic protein characterization. As reported in Table 1
for the natural forms, recombinants should undergo the
same stepwise process for characterization plus the valida-
tion against the natural form, when available. Because of the
assumption reported above, about the presence or the
absence of clinical disease in allergen-speciﬁc IgE-bearing
individuals,thedeﬁnitionofthesymptomatic/asymptomatic
ratio would most likely be deﬁned at stages 15a n d16o f
the allergen characterization process.
At the end of this second section, we can conclude that,
having an extended although not yet exhaustive knowl-
edge on allergenic molecules, the identiﬁcation process
can also be somewhat different from the ‘classical’ bio-
chemical/immunochemical one. As reported above and
from a survey of the literature, this process is always
dispersed on several papers published in more than one
journal depending on the leading topic. We can still
certainly distinguish an identiﬁcation process for a very
new compound, which is almost unchanged since the very
early days of allergen identiﬁcation and today called
‘proteomics’, but at the same time several different
approaches can be applied to homologous allergen identi-
ﬁcation by using molecular cloning technique [5]. The
stepwise process seems to be a reliable way to collect
accumulating data on each allergenic molecule.
Biotechnology, information technology and
microtechnology tools
From the ﬁrst two sections, we have learned that we need
to organize our knowledge on structures and let them be
deﬁned as IgE binding or not, and as causing allergic
diseases or not. Biotechnology procedures, which include
Table 1. Allergen identiﬁcation and full characterization process
5 Suspicious of an allergic reaction to an organism or its tissues
4 Preparation of the best extract starting from the best raw material
3 Positive skin testing and IgE testing with the extract
2 Extract evaluation by SDS-PAGE
1 IgE immunoblot identiﬁcation of SDS-PAGE isolated bands
0 Isolation and preliminary sequencing of the IgE-reactive band(s)
11 Puriﬁcation of the identiﬁed IgE-reactive band and full biochemical characterization, including source tissue localization and
concentration under several physiological and pathological conditions, and molecular cloning of the allergen
12 Evaluation of the naturally puriﬁed molecule by skin testing and IgE binding including any basophil/mast cell activation test (5–15
subjects) (should also apply to the recombinant form)
13 Evaluation of the naturally puriﬁed molecule by in vivo challenging of affected and non-affected organs (should also apply to the
recombinant form)
14 Evaluation of the naturally puriﬁed molecule on a broader population affected by the same sensitization (extract-detected) (should also
apply to the recombinant form)
15 Evaluation of the IgE reactivity of naturally puriﬁed molecule within a general allergic population, in one or more geographical areas
(should also apply to the recombinant form). Deﬁning the symptomatic/asymptomatic ratio
16 Evaluation of the IgE reactivity of naturally puriﬁed molecule within a general population, in one or more geographical areas (should also
apply to the recombinant form). Deﬁning the symptomatic/asymptomatic ratio
Characterization stages deﬁned by the minus sign refer to pre-allergenic structure deﬁnition; those deﬁned by the plus sign refer to the post-allergenic
structure deﬁnition.
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potentially identify all the IgE-binding structures regard-
less of whether they are either rarely expressed in the
allergenic organism tissue or are rarely IgE recognized
within a general ‘average’ population, or are rarely but
constantly IgE recognized by selected subsets of geneti-
cally prone subjects [6]. The advantage of any rapid high-
throughput system for allergen identiﬁcation [7] or even
the genomic identiﬁcation of related genes [8, 9] is to give
us access to hundreds of potentially related or putative
allergenic molecules. In the case of the 12-step approach
described in Table 1, the allergen identiﬁcation and
characterization starts atstage 11, but lacks the deﬁnition
of the IgE-binding property. We expect to have more of
these studies leading to an extended genomic knowledge
of known allergenic organisms and taxonomic related and
unrelated ones. We must thus implement strategic tools to
classify the structures since the beginning of their descrip-
tion by extensively using information technology tools.
At the same time, we must step up the characterization
stage of every single molecule using high-throughput IgE
detection systems. There are several Internet-based re-
sources aiming to regulate and classify IgE-binding struc-
tures [10–12]. Three will be analysed herein as they
represent a different approach to allergen classiﬁcation.
The Allergen Nomenclature web site (http://www.aller-
gen.org) is devoted to report the work of the speciﬁc
WHO-IUIS subcommittee. Being an ofﬁcial organ of an
international health authority organism, the expert work
of the subcommittee should be advised as the most critical
one in a blasting situation of allergen identiﬁcation as
reported in Fig. 1. Following predeﬁned rules [13], names
are given to submitted protein identiﬁed as allergens.
Fulﬁlling the given criteria, the new allergen receives a
name and is put in the list. No additional data are collected
thereafter. Looking at the last WHO-IUIS-released allergen
list (28 January 2008), 580 allergens and 876 isoallergens
are classiﬁed. It is noteworthy that if not submitted, many
well-characterized allergens are not in the WHO-IUIS list
(i.e. buckwheat allergens). The allergen recruitment me-
chanism is the basis of the discrepancy between the WHO-
IUIS allergen list and the others. The overall data proces-
sing sometimes leads to allergens classiﬁed before any
public document appears in the scientiﬁc literature. Only
one reference paper is given for each allergen. No compu-
tational tools are available from the web site.
The Food Allergy Research & Resource Program
(FAARP) at the University of Nebraska releases a web-
based database (www.allergenonline.com) whose aim is to
classify proteins as allergens. This work is based on a
panel of scientists and clinicians actively involved in
reviewing literature data by comparing peer-reviewed
publications following predetermined guidelines. Pre-de-
ﬁned criteria lead to classify proteins into three categories
as allergens, putative allergens and those having insufﬁ-
cient evidence of allergenicity. The last released database,
version 8.0, lists 1313 peer-reviewed sequences included
in the ﬁrst two categories. Allergenicity or putative
allergenicity of a given sequence is evaluated, but assign-
ment to the two categories is not reported in the accessible
database. Further, considering the given criteria for aller-
genicity (i.e. ‘speciﬁcally bind IgE using sera from indivi-
duals with clear allergies to the source of the gene/protein
and further that the protein causes basophil activation or
histamine release, skin test reactivity or challenge test
reactivity using subjects allergic to the source’), many of
the listed isoforms should not be considered either aller-
gens or putative allergens as for instance they have never
beenshownto bind IgE. Reference documentation is given
for allergen groups generating confusion when reaching a
putative allergen sometimes having just a sequence simi-
larity to a given allergen, thus seeming to be well
documented. The availability of sequence similarity
search tools, either customized or not, increases the
usefulness of the database, particularly if the main pur-
pose of the database is to evaluate allergenicity of novel
proteins from genetically modiﬁed organisms.
The Allergome platform (http://www.allergome.org) is
an independent project aiming to classify allergens, IgE-
binding antigens and non-IgE-binding structures. The
only pre-deﬁned criterion used for the entry of a new
structure is that it has to be tested at least once for its IgE-
binding capacity or has any structural relationship with
known allergens. This strategy leads to classify the largest
set of molecules among online available web sites (1400
allergens, 939 isoallergens, as of February 2008). Each
classiﬁed structure is fully documented in terms of pub-
lished papers, each study is assigned to a speciﬁc scientiﬁc
documentation category (i.e. biochemistry, molecular
biology, diagnosis, epidemiology, etc.), allowing the user
to understand whether the molecule has just a sequence
reported in protein databases or has been fully documen-
ted, somewhat helping to comply with the classiﬁcation
stage as described in Table 1. References may be retrieved
either by searching for the speciﬁc molecule or by the
Allergome customized literature mining tool, the RefAr-
ray. Data on allergenicity are also extracted from the
literature and reported in detail in the molecule mono-
graph. At the moment, no search tools are available to
discriminate between molecules on the basis of the
documentation extent. A tool allowing dynamic reﬁned
searches among classiﬁed structures would certainly
increase the usefulness of the Allergome platform,
fulﬁlling the need and requirements for a more critical
view of allergenic structure classiﬁcation and character-
ization level. No computational tools are available from
the Allergome web site. None of the Internet-based
databases has adopted any post-identiﬁcation criteria
for a further characterization of a given allergenic
molecule.
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based on their use during the clinical workup in world-
wide allergy centres or within large epidemiological
studies. Dealing with hundreds of allergenic molecules
would be difﬁcult or almost impossible using skin test or
singleplex testing currently available in laboratory sys-
tems to support this idea. Following the application of
microarray technology to genomics, the same technology
is now applied to proteomics. A large collaborative study
involving world-wide researchers gave us the proof of
concept that proteomic microarray can be dedicated to IgE
detection based on allergenic molecules [14]. Further
reports describe this new powerful tool [15–17] now
available as a commercial product for routine multiplex
IgE detection (ISAC system, VBC-Genomics, Vienna, Aus-
tria). The intrinsic feature of the allergenic molecule-
based multiplex test is to allow any single allergy centre
adopting the tool for routine diagnostic purposes to
produce a wealth of data related to all the tested molecules
on all the tested patients. This molecule-based microarray
IgE testing, adopted in our centre since March 2006, has
generated almost 2000000 data on an average of 80
allergens, giving a detailed magnitude of sensitization
prevalence for each allergen and linking them to clinical
features. Further expansion of available allergenic mole-
cules spotted on the microarray, regardless of being
common or uncommon allergens in a given geographical
area, would further expand our knowledge. It is note-
worthy that additional powerfulness will be added to such
testing when the ISAC system will be fully interfaced with
the Allergome-ReTiME platform, a module for raw data
mining allowing to store and retrieve real-time produced
data. Complementing these networked systems with an
electronic record for the allergy patient would allow any
world-wide allergy specialist to contribute towards in-
creasing the knowledge on allergens. Additional bioinfor-
matics analysing tools will help in evaluating protein
reciprocal biochemical and immunochemical relation-
ships by showing for instance the clustering behaviour of
previously undeﬁned structure.
Conclusions
It is highly realistic to say that the deﬁnition of the
biological feature of any given protein to be or not an
IgE-binding protein, and to be capable of giving rise to
clinical symptoms in a certain percentage of the sensitized
population, comes from a stepwise approach combining
bench and bedside studies, starting from still relevant
isolated case reports to selected cohort studies. Such
‘classical’ tools can now be integrated by biotechnology,
microtechnology and bioinformatics tools in an attempt
to dynamically describe the allergen/non-allergen ontol-
ogy. The stepwise approach for deﬁning a molecule as an
allergen or not may require months to years, but a
dynamically deﬁned platform integrating the best feature
of currently available web-based resources could speed up
our process to acquire the most comprehensive knowledge
on allergenic structures ever, leading most of the aller-
genic molecules to step up their characterization level in a
short time frame, and to be classiﬁed between the highest
stages of the arbitrary scale reported in Table 1. In the
future, considerable effort should be directed towards
designing the broadest world-wide project in order to
classify IgE- and non-IgE-binding structures using most
of the technological resources as reported in the present
article and involving health authorities, scientiﬁc associa-
tions and companies. Although it could seem too vision-
ary a hypothesis for the future, too far from a realistic
application, the opinions reported herein are based on
their development and their practical current application.
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